
APS, with 10,000 retail relationships across the country, is now the nations largest provider of walk-in payment services to people who pay their bills in person rather than through the postal service or Internet. Operating in 45 states, APS experienced 56% sales growth last year alone, with another strong sales year predicted in 2002.
Many strategic decisions were made at APS last year that should greatly enhance our position. A contract on the East Coast with Verizon is expected to add significant volume in the years ahead. We acquired a majority interest in CellCards of Illinois, a provider of prepaid cellular and long-distance cards, and we entered into a joint marketing agreement with Billmatrix, an emerging name in payments by phone. This year, APS has already begun selling a prepaid MasterCard (Access by Quickpay!) and has acquired the walk-in bill payment business of Merchants Express Money Order Company (MEMO), one of the largest money order providers in the U.S.
Theres every reason to expect that APS will become a dominant player in a profitable niche. It has already become a valuable conduit for people outside of the banking system who wish to pay their bills efficiently.
Xcelecom, our other major service company, has more than doubled its size to over $300 million dollars per year since 2000 and is already proving its worth on our balance sheet. Once a marginal contributor to our earnings, it brought in $6 million for us last year, triple its 2000 level. From North Carolina to Massachusetts, Xcelecom is a known quantity a leading provider of tailored electrical and voice-data-video design, cellular communication antennae, telecom and computer infrastructure construction, systems integration and related services.
The 12 acquired companies that now comprise Xcelecom were added in a disciplined
fashion. They must serve industrial/commercial markets and have a great local
reputation and strong customer list. They have been profitable in the past
and still are as Xcelecom assets. Future acquisitions must first pass the
same litmus tests.